The clinical impact of who standardization of PSA assays

Journal of Medical Biochemistry

Volumn 27, Issue 2, 2008, Pages 161-168

  Blanchet, Jean Sébastien ^a   Brinkmann, Thomas ^a  

^a BECKMAN COULTER INC   (United States)

Author keywords

Assay standardization; Free PSA; Prostate cancer; PSA; Total PSA; WHO calibration

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

CALIBRATION; CLINICAL DECISION MAKING; DIAGNOSTIC ACCURACY; IMMUNOASSAY; PROSTATE CANCER; REVIEW; WORLD HEALTH ORGANIZATION;

EID: 44649160891     PISSN: 14528258     EISSN: 14528266     Source Type: Journal    
DOI: 10.2478/v10011-008-0010-7     Document Type: Review

References (35)

1. Hara M, Koyanagi Y, Inoue T, Fukuyama T. Some physico-chemical characteristics of »g-seminoprotein«, an antigenic component specific for human seminal plasma. Forensic immunological study of body fluids and secretion. VII. Nihon Hoigaku Zasshi 1971; 25: 322-4.
2. Papsidero LD, Wang MC, Valenzuela LA, Murphy GP, Chu TM. A prostate antigen in sera of prostatic cancer patients. Cancer Res 1980; 40: 2428-32.
3. Wang MC, Valenzuela LA, Murphy GP, Chu TM. Purification of a human prostate specific antigen. Invest Urol 1979; 17: 159-63.
4. Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 1987; 317: 909-16.
5. Catalona WJ, Smith DS, Ratliff TL, Dodds KM, Coplen DE, Yuan JJ, et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 1991; 324: 1156-61.
6. Catalona WJ, Richie JP, Ahmann FR, Hudson MA, Scardino PT, Flanigan RC, et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol 1994; 151: 1283-90.
7. Carter HB, Pearson JD, Metter EJ, Brant LJ, Chan DW, Andres R, et al. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA 1992; 267: 2215-20.
8. Catalona WJ, Partin AW, Slawin KM, Brawer MK, Flanigan RC, Patel A, et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA 1998; 279: 1542-7.
9. Loeb S, Catalona WJ. Prostate-specific antigen in clinical practice. Cancer Lett 2007.
10. Catalona WJ, Hudson MA, Scardino PT, Richie JP, Ahmann FR, Flanigan RC, et al. Selection of optimal prostate specific antigen cutoffs for early detection of prostate cancer: receiver operating characteristic curves. J Urol 1994; 152: 2037-42.
11. Kort SA, Martens F, Vanpoucke H, Van Duijnhoven HL, Blankenstein MA. Comparison of 6 automated assays for total and free prostate-specific antigen with special reference to their reactivity toward the WHO 96/670 reference preparation. Clin Chem 2006; 52: 1568-74.
12. Roddam AW, Rimmer J, Nickerson C, Ward AM. Prostate-specific antigen: bias and molarity of commercial assays for PSA in use in England. Ann Clin Biochem 2006; 43: 35-48.
13. Semjonow A, Oberpenning F, Brandt B, Zechel C, Brandau W, Hertle L. Impact of free prostate-specific antigen on discordant measurement results of assays for total prostate-specific antigen. Urology 1996; 48: 10-5.
14. Semjonow A, De Angelis G, Oberpenning F, Schmid HP, Brandt B, Hertle L. The clinical impact of different assays for prostate specific antigen. BJU Int 2000; 86: 590-7.
15. Roddam AW, Price CP, Allen NE, Ward AM. Assessing the clinical impact of prostate-specific antigen assay variability and nonequimolarity: a simulation study based on the population of the United Kingdom. Clin Chem 2004; 50: 1012-6.
16. Blijenberg BG, Yurdakul G, Van Zelst BD, Bangma CH, Wildhagen MF, Schroder FH. Discordant performance of assays for free and total prostate-specific antigen in relation to the early detection of prostate cancer. BJU Int 2001; 88: 545-50.
17. Stamey TA, Chen Z, Prestigiacomo AF. Reference material for PSA: the IFCC standardization study. International Federation of Clinical Chemistry. Clin Biochem 1998; 31: 475-81.
18. Rafferty B, Rigsby P, Rose M, Stamey T, Gaines Das R. Reference reagents for prostate-specific antigen (PSA): establishment of the first international standards for free PSA and PSA (90:10). Clin Chem 2000; 46: 1310-7.
19. Chan DW, Sokoll LJ. WHO first international standards for prostate-specific antigen: the beginning of the end for assay discrepancies? Clin Chem 2000; 46: 1291-2.
20. Stephan C, Kramer J, Meyer HA, Kristiansen G, Ziemer S, Deger S, et al. Different prostate-specific antigen assays give different results on the same blood sample: an obstacle to recommending uniform limits for prostate biopsies. BJU Int 2007; 99: 1427-31.
21. Graves HC. Issues on standardization of immunoassays for prostate-specific antigen: a review. Clin Invest Med 1993; 16: 415-24.
22. Semjonow A, Oberpenning F, Weining C, Schon M, Brandt B, De Angelis G, et al. Do modifications of non-equimolar assays for total prostate-specific antigen improve detection of prostate cancer? Clin Chem 2001; 47: 1472-5.
23. Stamey TA. Second Stanford Conference on International Standardization of Prostate-Specific Antigen Immunoassays: September 1 and 2, 1994. Urology 1995; 45: 173-84.
24. Stamey TA, Teplow DB, Graves HC. Identity of PSA purified from seminal fluid by different methods: comparison by amino acid analysis and assigned extinction coefficients. Prostate 1995;27:198-203.
25. Belanger A, Van Halbeek H, Graves HC, Grandbois K, Stamey TA, Huang L, et al. Molecular mass and carbohydrate structure of prostate specific antigen: studies for establishment of an international PSA standard. Prostate 1995; 27: 187-97.
26. Chan DW, Bruzek DJ, Oesterling JE, Rock RC, Walsh PC. Prostate-specific antigen as a marker for prostatic cancer: a monoclonal and a polyclonal immunoassay compared. Clin Chem 1987; 33: 1916-20.
27. Link RE, Shariat SF, Nguyen CV, Farr A, Weinberg AD, Morton RA, et al. Variation in prostate specific antigen results from 2 different assay platforms: clinical impact on 2304 patients undergoing prostate cancer screening. J Urol 2004; 171: 2234-8.
28. Stephan C, Semjonow A. Accuracy assessment of PSA methods must be based on clinical instead of artificial samples - a response to AW Roddam et al., Ann Clin Biochem 2006; 43: 35-48. Ann Clin Biochem 2006; 43: 421-2; author reply 422-3.
29. Stephan C, Klaas M, Muller C, Schnorr D, Loening SA, Jung K. Interchangeability of measurements of total and free prostate-specific antigen in serum with 5 frequently used assay combinations: an update. Clin Chem 2006; 52: 59-64.
30. Fille C, Tombal B, Philippe M. Impact of total PSA WHO calibration on decision points in screening for prostate cancer [abstract]. EAU Congress, Milan. 2008: 218.
31. Postma R, Schroder FH. Screening for prostate cancer. Eur J Cancer 2005; 41: 825-33.
32. Jansen FH, Roobol M, Bangma CH, Van Schaik RHN. The clinical impact of the PSA assay WHO calibration on prostate biopsy rates and prostate cancer detection [abstract]. EAU Congress, Milan. 2008.
33. Stephan C, Kahrs A, Klotzek S, Reiche J, Müller C, Lein M, et al. Toward the metrological traceability in determination of prostate-specific antigen: the new Access Hybritech assays calibrated against WHO standards compared with the traditional Access Hybritech assays. CCLM 2008; in press.
34. Stephan C, Kahrs A, Klotzek S, Reiche J, Müller C, Lein M, et al. Comparison of the »gold« standard Access PSA (Hybritech) assay with the new Beckman Coulter WHO-standardized calibrated Access PSA assays [abstract]. EAU Congress, Milan. 2008.
35. Stenman UH, Paus E, Allard WJ, Andersson I, Andres C, Barnett TR, et al. Summary report of the TD-3 workshop: characterization of 83 antibodies against prostate-specific antigen. Tumour Biol 1999; 20 Suppl 1: 1-12.